Revascularization treatment of stable coronary artery disease

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 2, 2011, Pages 195-212

  Magro, Michael ^a   Garg, Scot ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angina; Coronary artery bypass surgery; Ischemic heart disease; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; NICORANDIL; NITRATE; PACLITAXEL; RANOLAZINE; RAPAMYCIN; STATIN; TRIMETAZIDINE;

ANGINA PECTORIS; ANGIOPLASTY; ARTERIOGRAPHY; BARE METAL STENT; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; EXERCISE TEST; FRACTIONAL FLOW RESERVE; HEALTH CARE COST; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INTERMETHOD COMPARISON; MULTIDETECTOR COMPUTED TOMOGRAPHY; MYOCARDIAL PERFUSION IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STRESS ECHOCARDIOGRAPHY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; HUMANS; QUALITY OF LIFE; STENTS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 78651460857     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.517522     Document Type: Review

References (102)

1. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007;49:2105-11 (Pubitemid 46771047)
2. Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816-21
3. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57
4. Coles JC, Goldbach MM, Ahmed SN, et al. Left main-stem coronary artery disease: surgical versus medical management. Can J Surg 1984;27:571-3
5. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72:V123-35 (Pubitemid 16126355)
6. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219-27
7. Leaman DM, Brower RW, Meester GT, et al. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation 1981;63:285-99
8. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72
9. Kappetein PA, on behalf of SYNTAX investigators. Optimal revascularization strategy in patients with three-vessel disease and/or left main disease. The 2-year outcomes of the SYNTAX Trial. European Society of Cardiology Congress, 29 August - 2 September 2009, Barcelona, Spain
10. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-24
11. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease 2-year follow-up of the FAME (fractional flow reserve versus angiography for multivessel evaluation) study. J Am Coll Cardiol. 2010;56(3):177-84
12. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80
13. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42 (Pubitemid 36070930)
14. Garg S, Serruys P, Onuma Y, et al. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009;2:1190-8
15. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-6
16. Garg S, Serruys P. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2010;8:449-70
17. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81 (Pubitemid 43998110)
18. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40:1531-40 (Pubitemid 35192881)
19. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007;297:1985-91 (Pubitemid 46740350)
20. Boden WE, ORourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16 (Pubitemid 46588415)
21. Maron DJ, Boden WE, ORourke RA, et al. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010;55:1348-58
22. Valgimigli M, Serruys PW, Tsuchida K, et al. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007;99:1072-81 (Pubitemid 46562516)
23. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91
24. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15
25. Coronary angioplasty versus medical therapy for angina. the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461-8
26. Pocock SJ, Henderson RA, Clayton T, et al. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol 2000;35:907-14
27. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-70
28. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358:951-7
29. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA 2003;289:1117-23 (Pubitemid 37430325)
30. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004;110:1213-18 (Pubitemid 39202335)
31. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004;43:1743-51 (Pubitemid 38622508)
32. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007;115:1082-9 (Pubitemid 46673170)
33. Jeremias A, Kaul S, Rosengart TK, et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009;122:152-61
34. Schomig A, Mehilli J, de Waha A, et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:894-904
35. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-18
36. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8 (Pubitemid 9229695)
37. Chaitman BR, Ryan TJ, Kronmal RA, et al. Coronary Artery Surgery Study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol 1990;16:1071-8 (Pubitemid 20378452)
38. Jones RH, Kesler K, Phillips HR III, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996;111:1013-25 (Pubitemid 26146056)
39. Hannan EL, Racz MJ, McCallister BD, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1999;33:63-72 (Pubitemid 29064074)
40. Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery: comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. J Am Coll Cardiol Intv 2008;1:483-91
41. Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007;334:617 (Pubitemid 46852480)
42. Goy JJ, Kaufmann U, Hurni M, et al. 10-year follow-up of a prospective randomized trial comparing bare-metal stenting with internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA (Stenting versus Internal Mammary Artery grafting) trial. J Am Coll Cardiol 2008;52:815-17
43. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24 (Pubitemid 32285232)
44. Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-20 (Pubitemid 38332615)
45. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-81
46. Rodriguez A, Bernardi V, Navia J, et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001;37:51-8 (Pubitemid 32051717)
47. Rodriguez AE, Baldi J, Fernandez Pereira C, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 2005;46:582-8 (Pubitemid 41132681)
48. Weintraub WS, Mahoney EM, Zhang Z, et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 2004;90:782-8 (Pubitemid 38813640)
49. Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008;118:381-8
50. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-304
51. Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008;118:1146-54
52. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373:1190-7
53. Garg S, Serruys PW. Coronary stents - current status. J Am Coll Cardiol 2010;56(10 Suppl):S1-42
54. Serruys PW, Ong ATL, Morice M-C, et al. Arterial revascularisation therapies study part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 2005;1:147-56
55. Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2010;55:1093-101
56. Rodriguez A, Maree A, Grinfeld L, et al. Revascularization strategies of coronary multiple vessel disease in the Drug Eluting Stent Era: one year follow-up results of the ERACI III Trial. EuroIntervention 2006;2:53-60
57. Kappetein AP. Optimal revascularization strategy in patients with three-vessel disease and/or left main disease. The 2-year outcomes of the SYNTAX trial. Presented at the ESC Congress, 2 September 2009, Barcelona, Spain. Available from: www.syntaxscore.com
58. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010;55:432-40
59. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002;39:559-64
60. Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006;113:2406-12 (Pubitemid 43948048)
61. Clinical reality of coronary prevention guidelines. a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001
62. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34 (Pubitemid 28350165)
63. Niles NW, McGrath PD, Malenka D, et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 2001;37:1008-15 (Pubitemid 32217598)
64. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-40 (Pubitemid 29077362)
65. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007;28:1946-52 (Pubitemid 47579538)
66. Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007;50:1627-34 (Pubitemid 47562680)
67. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118:2277-85
68. Stenestrand U, James SK, Lindback J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010;31:177-86
69. Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2007;99:1399-402 (Pubitemid 46686640)
70. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70 (Pubitemid 41175674)
71. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010;55:1067-75
72. Farkouh ME, Dangas G, Leon MB, et al. Design of the future revascularization evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM) Trial. Am Heart J 2008;155:215-23
73. Aoki J, Ong AT, Hoye A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J 2005;26:1488-93 (Pubitemid 41373488)
74. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-9 (Pubitemid 38372783)
75. Zhang F, Dong L, Ge J. Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomized trials. Heart 2009;95:1676-81
76. Brar S, Gray W, Dangas G, et al. Bifurcation stenting with drug-eluting stents: a meta-analysis. EuroIntervention 2009;5:475-84
77. Katritsis DG, Siontis GCM, Ioannidis JPA. Double versus single stenting for coronary bifurcation lesions: a meta-analysis. Circ Cardiovasc Intervent 2009;2:409-15
78. Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006;114:1955-61 (Pubitemid 44665390)
79. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 2010;121:1235-43
80. Prasad A, Rihal CS, Lennon RJ, et al. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol 2007;49:1611-18 (Pubitemid 46551620)
81. Sianos G, Barlis P, Di Mario C, et al. European experience with the retrograde approach for the recanalisation of coronary artery chronic total occlusions. A report on behalf of the euroCTO club. EuroIntervention 2008;4:84-92
82. Garcia-Garcia HM, van Mieghem CA, Gonzalo N, et al. Computed tomography in total coronary occlusions (CTTO registry): radiation exposure and predictors of successful percutaneous intervention. EuroIntervention 2009;4:607-16
83. Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006;114:921-8
84. Rubartelli P, Petronio AS, Guiducci V, et al. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. Eur Heart J 2010;31(16):2014-20
85. Naik H, White AJ, Chakravarty T, et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. JACC Cardiovasc Interv 2009;2:739-47
86. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial. Circulation 2010;121(24):2645-53
87. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/ AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41
88. Kappetein AP, Sabik JF, Serruys PW, Stone GW. Evaluation of xience prime versus coronary artery bypass surgery for effectiveness of left main revascularisation. The EXCEL trial. 2009. Available from: http:// wwwsbhci.org.br/pdf/ EXCELSitequalificationquestionnairepdf [Last accessed 22 September 2010]
89. van Domburg RT, Daemen J, Morice MC, et al. Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention 2010;5:962-7
90. Weintraub WS, Boden WE, Zhang Z, et al. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes 2008;1:12-20
91. Weintraub WS, Becker ER, Mauldin PD, et al. Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). Am J Cardiol 2000;86:747-52
92. Morice MC. Multivessel disease lessons from SYNTAX (early results and 2 year follow-up): interventional perspectives. Presented at Transcatheter Cardiovascular Therapeutics; 21 September 2009, San Francisco, USA
93. Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging 2004;31:261-91
94. Mark DB, Hlatky MA, Harrell FE Jr, et al. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987;106:793-800 (Pubitemid 17078969)
95. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5
96. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53:1510-16
97. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina. the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75
98. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16 (Pubitemid 351919795)
99. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
100. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772-9
101. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 (Pubitemid 40471450)
102. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45 (Pubitemid 41627921)